Reblozyl

Active Ingredient(s): Luspatercept-aamt
FDA Approved: * November 8, 2019
Pharm Company: * CELGENE CORP
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Reblozyl Overview

Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. It was developed by Acceleron Pharma in collaboration with Celgene.[2] The U.S. Food and Drug Administration (FDA) awarded orphan drug status in 2013, and fast track designation in 2015, for both indications.[3] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[4&a...

Read more Reblozyl Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Luspatercept

Recent Reblozyl Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Luspatercept-aamt
  • Powder: 25mg/vial, 75mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Reblozyl: (2 results)

Sorted by National Drug Code
  • 59572-711 Reblozyl 25 mg Subcutaneous Injection, Powder, Lyophilized, for Solution by Celgene
  • 59572-775 Reblozyl 75 mg Subcutaneous Injection, Powder, Lyophilized, for Solution by Celgene

Other drugs which contain Luspatercept-aamt or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 27 October 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA